Celsion Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) LAWRENCEVILLE, N.J., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that on September 28, 2018, the Compensation...

Celsion Appoints Marianne Lambertson as Vice President of Communications and Investor Relations   Lambertson brings executive experience to the newly created position,  reinforcing Celsion’s commitment to its strategic communications and investor relations objectives ...

Celsion Announces First Patient Randomized in the Gene-Mediated Immunotherapy (GEN-1) Study of Newly Diagnosed Stage III/IV Ovarian Cancer Patients OVATION II Study Will Evaluate Initial and Maintenance Dosing of GEN-1 on Progression-Free Survival in a Two-Arm, Randomized Trial of Up to 130 Patients LAWRENCEVILLE, N.J., Sept. 06, 2018 (GLOBE...